Mingfei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mingfei Yang has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Kai Zhao
Graduate School, Qinghai University, Xining, People's Republic of China
13 shared publicationsYu Guo
Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, People’s Republic of China
12 shared publicationsQiang Zhang
Department of Neurosurgery Qinghai Provincial People's Hospital Xining Qinghai China
9 shared publicationsChaonan Du
Graduate School, Qinghai University, Xining, Qinghai 810016, PR China
7 shared publicationsFuli Yan
Graduate School, Qinghai University
5 shared publicationsJian Wu
Graduate School, Qinghai University
5 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1920098
Is admission lactate an independent prognostic marker or a reflection of injury severity in severe traumatic brain injury?
Objective: Although admission lactate is associated with poor outcomes after severe traumatic brain injury, its independent prognostic value remains uncertain. This study aimed to determine whether admission lactate is an independent prognostic marker or primarily a reflection of injury severity. Methods: In a two-center retrospective study of patients with sTBI (GCS ≤ 8) (development cohort, n = 287; external validation cohort, n = 185), we assessed whether the association between admission lactate and 30-day mortality remained independent of established severity markers (age, GCS, pupillary reactivity, and Rotterdam CT score) and quantified the incremental prognostic value of lactate beyond this severity baseline, with external validation. Exploratory in vitro experiments in hypoxic SH-SY5Y cells were performed as a secondary analysis to examine cellular responses to lactate under hypoxic conditions. Results: Thirty-day mortality was 42.2% in the development cohort and 36.8% in the external validation cohort. Admission lactate was significantly associated with mortality on univariable analysis (OR per mmol/L, 1.50; 95% CI, 1.30–1.73). After adjustment for severity markers, the adjusted OR was 1.19 per mmol/L (95% CI, 1.00–1.42; P = 0.051), indicating a positive association with limited precision. Consistent with this finding, lactate provided minimal incremental prognostic value beyond the severity baseline (ΔAUC, +0.005; P = 0.31), and these results were reproduced in the external validation cohort. Nevertheless, in vitro experiments suggested a potential biological activity of lactate that warrants further investigation. Conclusion: In these two selected adult sTBI cohorts, admission lactate was associated with 30-day mortality but provided little incremental prognostic information beyond established neurological severity markers. Its role should therefore be interpreted as adjunctive rather than as a stand-alone prognostic factor. The exploratory in vitro findings warrant further mechanistic investigation.
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1920098
Open AccessIs admission lactate an independent prognostic marker or a reflection of injury severity in severe traumatic brain injury?
Objective: Although admission lactate is associated with poor outcomes after severe traumatic brain injury, its independent prognostic value remains uncertain. This study aimed to determine whether admission lactate is an independent prognostic marker or primarily a reflection of injury severity. Methods: In a two-center retrospective study of patients with sTBI (GCS ≤ 8) (development cohort, n = 287; external validation cohort, n = 185), we assessed whether the association between admission lactate and 30-day mortality remained independent of established severity markers (age, GCS, pupillary reactivity, and Rotterdam CT score) and quantified the incremental prognostic value of lactate beyond this severity baseline, with external validation. Exploratory in vitro experiments in hypoxic SH-SY5Y cells were performed as a secondary analysis to examine cellular responses to lactate under hypoxic conditions. Results: Thirty-day mortality was 42.2% in the development cohort and 36.8% in the external validation cohort. Admission lactate was significantly associated with mortality on univariable analysis (OR per mmol/L, 1.50; 95% CI, 1.30–1.73). After adjustment for severity markers, the adjusted OR was 1.19 per mmol/L (95% CI, 1.00–1.42; P = 0.051), indicating a positive association with limited precision. Consistent with this finding, lactate provided minimal incremental prognostic value beyond the severity baseline (ΔAUC, +0.005; P = 0.31), and these results were reproduced in the external validation cohort. Nevertheless, in vitro experiments suggested a potential biological activity of lactate that warrants further investigation. Conclusion: In these two selected adult sTBI cohorts, admission lactate was associated with 30-day mortality but provided little incremental prognostic information beyond established neurological severity markers. Its role should therefore be interpreted as adjunctive rather than as a stand-alone prognostic factor. The exploratory in vitro findings warrant further mechanistic investigation.
- 28 July 2026
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 18 (4) , e70071
Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives
Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal‐oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli‐responsive nano‐systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.
- 28 July 2026
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 18 (4) , e70071
Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives
Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal‐oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli‐responsive nano‐systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.
- Open Access
- 1 July 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-29
Stimuli-Responsive Biomimetic Nanomedicines for Targeted Therapy in Ischemic Stroke: Design Principles, Preclinical Evidence and Translational Challenges
Ischemic stroke (IS) is a complex cerebrovascular disease with multifactorial etiology and pathological mechanisms, characterized by high morbidity, disability, and mortality rates. Although mechanical thrombectomy, intravenous thrombolysis, and neuroprotective interventions have improved acute management, effective brain-targeted delivery remains limited by the blood-brain barrier, short therapeutic windows, heterogeneous ischemic lesions, and secondary injury after reperfusion. Biomimetic nanomedicines have emerged as promising platforms for IS therapy because they can inherit biological functions from cell membranes, extracellular vesicles, or endogenous ligands, thereby improving biocompatibility, immune evasion, circulation stability, and lesion targeting. However, their clinical translation is still constrained by biosafety and immunogenicity concerns, uncertain pharmacokinetics and reproducible large-scale manufacturing, quality control, and regulatory requirements. Moreover, the balance between drug-loading capacity and target release efficiency remains a key challenge. Excessive cargo loading may compromise nanocarrier stability, whereas insufficient loading may fail to achieve therapeutic efficacy. Therefore, rational nanocarrier design for IS should coordinate brain accumulation, stable systemic circulation, lesion-selective activation, efficient loading, and controllable release. In this review, we discuss how stimuli-responsive biomimetic nanomedicines exploit pathological cues such as reactive oxygen species, acidosis, enzymes, inflammatory mediators, or external stimuli for spatiotemporally controlled therapy and combined therapy. This review critically summarizes IS pathophysiology, major biomimetic nanocarrier types, and the design principles and response mechanisms of stimuli-responsive biomimetic systems. Finally, current limitations and future directions are discussed, with emphasis on biosafety evaluation, standardized characterization, scalable manufacturing, clinically relevant models, and rational integration of precision-responsive designs to accelerate translation.
- 1 July 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-29
Open AccessStimuli-Responsive Biomimetic Nanomedicines for Targeted Therapy in Ischemic Stroke: Design Principles, Preclinical Evidence and Translational Challenges
Ischemic stroke (IS) is a complex cerebrovascular disease with multifactorial etiology and pathological mechanisms, characterized by high morbidity, disability, and mortality rates. Although mechanical thrombectomy, intravenous thrombolysis, and neuroprotective interventions have improved acute management, effective brain-targeted delivery remains limited by the blood-brain barrier, short therapeutic windows, heterogeneous ischemic lesions, and secondary injury after reperfusion. Biomimetic nanomedicines have emerged as promising platforms for IS therapy because they can inherit biological functions from cell membranes, extracellular vesicles, or endogenous ligands, thereby improving biocompatibility, immune evasion, circulation stability, and lesion targeting. However, their clinical translation is still constrained by biosafety and immunogenicity concerns, uncertain pharmacokinetics and reproducible large-scale manufacturing, quality control, and regulatory requirements. Moreover, the balance between drug-loading capacity and target release efficiency remains a key challenge. Excessive cargo loading may compromise nanocarrier stability, whereas insufficient loading may fail to achieve therapeutic efficacy. Therefore, rational nanocarrier design for IS should coordinate brain accumulation, stable systemic circulation, lesion-selective activation, efficient loading, and controllable release. In this review, we discuss how stimuli-responsive biomimetic nanomedicines exploit pathological cues such as reactive oxygen species, acidosis, enzymes, inflammatory mediators, or external stimuli for spatiotemporally controlled therapy and combined therapy. This review critically summarizes IS pathophysiology, major biomimetic nanocarrier types, and the design principles and response mechanisms of stimuli-responsive biomimetic systems. Finally, current limitations and future directions are discussed, with emphasis on biosafety evaluation, standardized characterization, scalable manufacturing, clinically relevant models, and rational integration of precision-responsive designs to accelerate translation.
- Open Access
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1746857
Commentary: Early supported discharge and transitional care management after stroke: a systematic review and meta-analysis
We read with great interest the systematic review by Jee et al. (1). This study provided a comprehensive synthesis of the effectiveness of early supported discharge (ESD) and transitional care (TC) for patients after stroke, offering valuable insights for both research and clinical practice in this field. At the same time, we believe that several aspects related to the handling of heterogeneity and the interpretation of statistically non-significant pooled effects could be further clarified, which would help readers more accurately appraise the strengths and limitations of the evidence. The aim of this commentary is therefore to highlight key methodological considerations and issues of interpretation that may influence evidence synthesis and clinical inference, rather than simply restating the conclusions of the original review.In the meta-analysis section, the authors first analyzed outcomes such as length of hospital stay, activities of daily living (ADL), modified Rankin Scale (mRS) scores, and caregiver burden using a fixed-effects model, and reported I² values ranging from 59% to 90%, indicating substantial heterogeneity among the included studies. Switching to a random-effects model was therefore consistent with standard practice. However, the manuscript subsequently stated that "the random-effects model analysis did not show significant heterogeneity," which might be misinterpreted as reflecting a potential methodological misunderstanding. It should be emphasized that, in meta-analysis, the choice of a random-effects model is typically driven by the presence of considerable heterogeneity and the need for a more robust pooled estimate, not because heterogeneity disappears after applying the model. The purpose of a random-effects model is to accommodate existing heterogeneity rather than to eliminate it.In addition, Jee et al. reported a pooled random-effects estimate for length of stay of SMD = -0.13 (95% CI -0.31 to 0.04; p = 0.14). Since the confidence interval crosses zero and the p-value exceeds 0.05, this indicates that ESD or TC did not achieve a statistically significant reduction in length of hospital stay compared with usual care. In the "Results" section of the abstract, however, the authors stated that "ESD or TC could decrease the length of hospital stay more than the usual care." Although this wording reflects a favorable direction of effect, which was clinically intuitive, explicitly stating that the difference was not statistically significant (p = 0.14) in the same place (or immediately thereafter) would help prevent readers from overemphasizing the direction of effect and would improve consistency between the abstract and the quantitative findings in the main text.With respect to approaches for managing high heterogeneity, relevant examples can be found in the literature. For instance, Kim et al. conducted subgroup analyses to explore potential sources of heterogeneity in their study (2), and Michael et al. performed sensitivity analyses by excluding the largest or most heavily weighted study to assess the influence of a single study on the overall estimate(3). Such sensitivity and subgroup analyses can help explore factors influencing the effect size and identify potential sources of heterogeneity, for example according to stroke severity, intervention intensity, care setting, or other clinically relevant characteristics, allowing a more accurate interpretation of quantitative syntheses. If similar analyses were applied to outcomes with high heterogeneity in the present review, the interpretability and robustness of its conclusions would be further strengthened.Overall, the review by Jee et al. suggests that ESD and TC after stroke show a potentially favorable direction of effect for several outcomes; however, statistically significant and consistent benefits have not yet been demonstrated across all endpoints. Importantly, the use of a random-effects model does not resolve underlying clinical or methodological heterogeneity and should not be interpreted as justification for confidence in a single pooled estimate. Clearly indicating the non-significant nature of the main pooled estimates would enable readers to more accurately assess the true impact of ESD or TC models and enhance the transparency and clinical and policy relevance of the findings. Failure to appropriately account for and interpret substantial heterogeneity and non-significant pooled estimates may lead to overestimation of treatment effects and potentially inappropriate clinical interpretation and decision-making.
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1746857
Open AccessCommentary: Early supported discharge and transitional care management after stroke: a systematic review and meta-analysis
We read with great interest the systematic review by Jee et al. (1). This study provided a comprehensive synthesis of the effectiveness of early supported discharge (ESD) and transitional care (TC) for patients after stroke, offering valuable insights for both research and clinical practice in this field. At the same time, we believe that several aspects related to the handling of heterogeneity and the interpretation of statistically non-significant pooled effects could be further clarified, which would help readers more accurately appraise the strengths and limitations of the evidence. The aim of this commentary is therefore to highlight key methodological considerations and issues of interpretation that may influence evidence synthesis and clinical inference, rather than simply restating the conclusions of the original review.In the meta-analysis section, the authors first analyzed outcomes such as length of hospital stay, activities of daily living (ADL), modified Rankin Scale (mRS) scores, and caregiver burden using a fixed-effects model, and reported I² values ranging from 59% to 90%, indicating substantial heterogeneity among the included studies. Switching to a random-effects model was therefore consistent with standard practice. However, the manuscript subsequently stated that "the random-effects model analysis did not show significant heterogeneity," which might be misinterpreted as reflecting a potential methodological misunderstanding. It should be emphasized that, in meta-analysis, the choice of a random-effects model is typically driven by the presence of considerable heterogeneity and the need for a more robust pooled estimate, not because heterogeneity disappears after applying the model. The purpose of a random-effects model is to accommodate existing heterogeneity rather than to eliminate it.In addition, Jee et al. reported a pooled random-effects estimate for length of stay of SMD = -0.13 (95% CI -0.31 to 0.04; p = 0.14). Since the confidence interval crosses zero and the p-value exceeds 0.05, this indicates that ESD or TC did not achieve a statistically significant reduction in length of hospital stay compared with usual care. In the "Results" section of the abstract, however, the authors stated that "ESD or TC could decrease the length of hospital stay more than the usual care." Although this wording reflects a favorable direction of effect, which was clinically intuitive, explicitly stating that the difference was not statistically significant (p = 0.14) in the same place (or immediately thereafter) would help prevent readers from overemphasizing the direction of effect and would improve consistency between the abstract and the quantitative findings in the main text.With respect to approaches for managing high heterogeneity, relevant examples can be found in the literature. For instance, Kim et al. conducted subgroup analyses to explore potential sources of heterogeneity in their study (2), and Michael et al. performed sensitivity analyses by excluding the largest or most heavily weighted study to assess the influence of a single study on the overall estimate(3). Such sensitivity and subgroup analyses can help explore factors influencing the effect size and identify potential sources of heterogeneity, for example according to stroke severity, intervention intensity, care setting, or other clinically relevant characteristics, allowing a more accurate interpretation of quantitative syntheses. If similar analyses were applied to outcomes with high heterogeneity in the present review, the interpretability and robustness of its conclusions would be further strengthened.Overall, the review by Jee et al. suggests that ESD and TC after stroke show a potentially favorable direction of effect for several outcomes; however, statistically significant and consistent benefits have not yet been demonstrated across all endpoints. Importantly, the use of a random-effects model does not resolve underlying clinical or methodological heterogeneity and should not be interpreted as justification for confidence in a single pooled estimate. Clearly indicating the non-significant nature of the main pooled estimates would enable readers to more accurately assess the true impact of ESD or TC models and enhance the transparency and clinical and policy relevance of the findings. Failure to appropriately account for and interpret substantial heterogeneity and non-significant pooled estimates may lead to overestimation of treatment effects and potentially inappropriate clinical interpretation and decision-making.
- Open Access
- 28 March 2025
- Published by Elsevier in World Neurosurgery
- Vol. 197, 123943
Efficacy and Safety of Endovascular Thrombectomy for Large Vessel Occlusion Stroke Beyond 24 Hours From Time Last Known Well: A Systematic Review and Meta-Analysis
- 28 March 2025
- Published by Elsevier in World Neurosurgery
- Vol. 197, 123943
Open AccessEfficacy and Safety of Endovascular Thrombectomy for Large Vessel Occlusion Stroke Beyond 24 Hours From Time Last Known Well: A Systematic Review and Meta-Analysis
- Open Access
- 3 March 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (5) , 108269
Hypoxia inducible factor-1alpha expression correlates with inflammatory injury of blood-brain barrier which influences perihaematomal edema after intracerebral hemorrhage
- 3 March 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (5) , 108269
Open AccessHypoxia inducible factor-1alpha expression correlates with inflammatory injury of blood-brain barrier which influences perihaematomal edema after intracerebral hemorrhage
- 12 December 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (2) , 569-570
Tracheostomy outcomes in critically ill patients with COVID-19: a systematic review, meta-analysis, and meta-regression. Comment on Br J Anaesth 2022; 129: 679–92
- 12 December 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (2) , 569-570
Tracheostomy outcomes in critically ill patients with COVID-19: a systematic review, meta-analysis, and meta-regression. Comment on Br J Anaesth 2022; 129: 679–92
- 10 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (1) , 133-139
Efficacy and safety outcomes of endovascular versus best medical treatment in posterior cerebral artery occlusion stroke
Background The management of acute ischemic stroke due to isolated posterior cerebral artery occlusion (iPCAO) remains a topic of debate. This study investigates the efficacy and safety of endovascular treatment (EVT) versus best medical treatment (BMT) in patients with iPCAO. Methods A systematic search was conducted across electronic databases including PubMed, Embase, and the Cochrane Library. Controlled studies comparing EVT and BMT in patients with iPCAO were selected. The primary efficacy outcome assessed was excellent outcome, defined as a modified Rankin Scale (mRS) score of 0–1. The primary safety outcome was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included functional independence (mRS 0–2), early neurological improvement (ENI), and mortality rates. Statistical analyses were conducted using random effects models. Results Eleven retrospective cohort studies involving 1811 patients with EVT and 2871 patients with BMT were analyzed. Compared with BMT, EVT was associated with a higher likelihood of an excellent outcome (adjusted OR (aOR) 1.33, 95% CI 1.14 to 1.54) and ENI (aOR 1.66, 95% CI 1.39 to 1.98), but no significant difference in functional independence (aOR 1.02, 95% CI 0.88 to 1.18). Compared with BMT, EVT may not be associated with an increased risk of sICH in patients with iPCAO (aOR 1.34, 95% CI 0.60 to 3.02) or mortality (aOR 1.31, 95% CI 0.83 to 2.08), although heterogeneity was high. Conclusions EVT may improve the likelihood of an excellent outcome and ENI in patients with iPCAO. However, the potential risks of sICH and mortality warrant consideration. Randomized trials are required to establish the definitive efficacy and safety of EVT in this patient population.
- 10 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (1) , 133-139
Efficacy and safety outcomes of endovascular versus best medical treatment in posterior cerebral artery occlusion stroke
Background The management of acute ischemic stroke due to isolated posterior cerebral artery occlusion (iPCAO) remains a topic of debate. This study investigates the efficacy and safety of endovascular treatment (EVT) versus best medical treatment (BMT) in patients with iPCAO. Methods A systematic search was conducted across electronic databases including PubMed, Embase, and the Cochrane Library. Controlled studies comparing EVT and BMT in patients with iPCAO were selected. The primary efficacy outcome assessed was excellent outcome, defined as a modified Rankin Scale (mRS) score of 0–1. The primary safety outcome was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included functional independence (mRS 0–2), early neurological improvement (ENI), and mortality rates. Statistical analyses were conducted using random effects models. Results Eleven retrospective cohort studies involving 1811 patients with EVT and 2871 patients with BMT were analyzed. Compared with BMT, EVT was associated with a higher likelihood of an excellent outcome (adjusted OR (aOR) 1.33, 95% CI 1.14 to 1.54) and ENI (aOR 1.66, 95% CI 1.39 to 1.98), but no significant difference in functional independence (aOR 1.02, 95% CI 0.88 to 1.18). Compared with BMT, EVT may not be associated with an increased risk of sICH in patients with iPCAO (aOR 1.34, 95% CI 0.60 to 3.02) or mortality (aOR 1.31, 95% CI 0.83 to 2.08), although heterogeneity was high. Conclusions EVT may improve the likelihood of an excellent outcome and ENI in patients with iPCAO. However, the potential risks of sICH and mortality warrant consideration. Randomized trials are required to establish the definitive efficacy and safety of EVT in this patient population.
- Open Access
- 30 April 2024
- Published by Springer Nature in Systematic Reviews
- Vol. 13 (1) , 1-9
Safety and efficacy of intravenous thrombolysis before mechanical thrombectomy in patients with atrial fibrillation
Background: Intravenous thrombolysis (IVT) before endovascular thrombectomy (EVT) is the standard treatment for patients with acute ischemic stroke caused by large vessel occlusion (AIS-LVO). However, the efficacy and safety of IVT before EVT in AIS-LVO patients with atrial fibrillation (AF) remains controversial. Thus, this study aims to assess the benefit of IVT plus EVT and direct EVT alone in AIS-LVO patients with AF. Method: Relevant studies that evaluated the outcomes of IVT plus EVT versus direct EVT alone in AIS-LVO patients with AF were systematically searched in PubMed, Embase, and Cochrane Library from inception to August 10, 2023. The outcomes included successful reperfusion (score of 2b to 3 for thrombolysis in cerebral infarction), symptomatic intracerebral hemorrhage (sICH), good clinical outcome (modified Rankin scale score ≤ 2) at 3 months, and 3-month mortality. Result: Eight eligible observational studies involving 6998 (3827 in the IVT plus EVT group and 3171 in the direct EVT group) patients with AIS-LVO complicated by AF were included. Compared with direct EVT, IVT plus EVT resulted in better 3-month clinical outcomes (odds ratio [OR] 1.27, 95% confidence interval [CI] 1.05–1.54) and lower 3-month mortality (OR 0.78, 95% CI 0.68–0.88). However, the incidence of sICH (OR 1.26, 95% CI 0.91–1.75) and the rate of successful reperfusion (OR 0.98, 95% CI 0.83–1.17) were not significantly different between treatment modalities. Conclusion: IVT plus EVT leads to better functional outcomes and lower mortality in AIS-LVO patients with AF. Withholding IVT plus EVT from patients with AF alone may not be justified.
- 30 April 2024
- Published by Springer Nature in Systematic Reviews
- Vol. 13 (1) , 1-9
Open AccessSafety and efficacy of intravenous thrombolysis before mechanical thrombectomy in patients with atrial fibrillation
Background: Intravenous thrombolysis (IVT) before endovascular thrombectomy (EVT) is the standard treatment for patients with acute ischemic stroke caused by large vessel occlusion (AIS-LVO). However, the efficacy and safety of IVT before EVT in AIS-LVO patients with atrial fibrillation (AF) remains controversial. Thus, this study aims to assess the benefit of IVT plus EVT and direct EVT alone in AIS-LVO patients with AF. Method: Relevant studies that evaluated the outcomes of IVT plus EVT versus direct EVT alone in AIS-LVO patients with AF were systematically searched in PubMed, Embase, and Cochrane Library from inception to August 10, 2023. The outcomes included successful reperfusion (score of 2b to 3 for thrombolysis in cerebral infarction), symptomatic intracerebral hemorrhage (sICH), good clinical outcome (modified Rankin scale score ≤ 2) at 3 months, and 3-month mortality. Result: Eight eligible observational studies involving 6998 (3827 in the IVT plus EVT group and 3171 in the direct EVT group) patients with AIS-LVO complicated by AF were included. Compared with direct EVT, IVT plus EVT resulted in better 3-month clinical outcomes (odds ratio [OR] 1.27, 95% confidence interval [CI] 1.05–1.54) and lower 3-month mortality (OR 0.78, 95% CI 0.68–0.88). However, the incidence of sICH (OR 1.26, 95% CI 0.91–1.75) and the rate of successful reperfusion (OR 0.98, 95% CI 0.83–1.17) were not significantly different between treatment modalities. Conclusion: IVT plus EVT leads to better functional outcomes and lower mortality in AIS-LVO patients with AF. Withholding IVT plus EVT from patients with AF alone may not be justified.